SCHEMBL24364973

SCHEMBL24364973

Cc1ccc(C2=NCC(C)CC2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.38
NOS1 P29475 3/20 0.38
NOS2 P35228 3/20 0.38
HPGDS O60760 1/20 0.36
CHRNB2 P17787 2/20 0.34
CHRNB4 P30926 2/20 0.34
CHRNA3 P32297 2/20 0.34
CHRNA4 P43681 2/20 0.34
CHRNA7 P36544 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
PTGS2 P35354 2/20 0.33
CHRNB1 P11230 1/20 0.32
CHRNB3 Q05901 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.32
HSD17B10 Q99714 1/20 0.32
JUN P05412 1/20 0.32
MAPK10 P53779 1/20 0.32
KDM1A O60341 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25323858 1.00 NOS3 (0.38) NOS3NOS1NOS2HPGDSCHRNB2
SCHEMBL24367616 0.83 NOS3 (0.37) NOS3NOS1NOS2CHRNB2CHRNB4
SCHEMBL24365547 0.81 NOS3 (0.41) NOS3NOS1NOS2
SCHEMBL24367075 0.80 NOS3 (0.35) NOS3NOS1NOS2PTGS2KDM1A
SCHEMBL24233854 0.80 CYP2A6 (0.41) CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7
SCHEMBL24363868 0.80 NISCH (0.43) NOS3NOS1NOS2NPC1PKM
SCHEMBL25323171 0.80 NISCH (0.43) NOS3NOS1NOS2NPC1PKM
SCHEMBL24365219 0.79 TRPV4 (0.38) NOS3NOS1NOS2
SCHEMBL24233735 0.77 ALDH1A1 (0.54) NOS3NOS1NOS2HPGDSCHRNB4
SCHEMBL25323561 0.77 ALDH1A1 (0.54) NOS3NOS1NOS2HPGDSCHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN NOS3 3132/4885NOS1 2495/4885NOS2 2374/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NOS3 556/4885NOS1 619/4885NOS2 760/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 NOS3 556/4885NOS1 619/4885NOS2 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.